Literature DB >> 11864948

Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).

Caroline J Henwood1, Tess Gatward, Marina Warner, Dorothy James, Mark W Stockdale, Richard P Spence, Kevin J Towner, David M Livermore, Neil Woodford.   

Abstract

A survey was conducted of the antimicrobial susceptibilities of 595 Acinetobacter spp. isolated from routine clinical specimens in 54 sentinel laboratories throughout the UK during 2000. Isolates of the Acinetobacter baumannii complex (genomic groups 2, 3 and 13TU; n = 443) were distinguished from other genomic groups (n = 152) by PCR fingerprinting of tDNA spacer regions. MICs of amikacin, cefotaxime, ceftazidime, ciprofloxacin, colistin, gentamicin, imipenem, meropenem, minocycline, piperacillin, piperacillin/tazobactam, rifampicin, sulbactam and tetracycline were determined on IsoSensitest agar and interpreted, wherever possible, using BSAC breakpoints. Tigecycline (GAR-936), a new glycylcycline, was also tested. Resistance to cephalosporins, aminoglycosides and ciprofloxacin was widespread, but carbapenems, colistin, sulbactam, minocycline and tigecycline were each active against >80% of the isolates. Isolates of A. baumannii were more often resistant to cefotaxime, ceftazidime, piperacillin, piperacillin/tazobactam, ciprofloxacin, gentamicin and tetracyclines than those belonging to other genomic groups, but were less often resistant to colistin; no significant differences between genomic groups were noted in the susceptibilities to amikacin, carbapenems, rifampicin or sulbactam. The relative activities of the tetracyclines were minocycline > tigecycline > tetracycline. Thirteen carbapenem-resistant isolates (MICs > or =8 mg/L; 2.2%) were received from six centres; four centres sent single isolates; one sent three and one sent six. An allele of bla(IMP) was detected in one of these isolates, but the other 12 isolates either had carbapenemase-independent resistance, or undetectable carbapenemase activity combined with other resistance mechanisms. In conclusion, carbapenems, colistin and minocycline retained greatest activity against the Acinetobacter isolates collected. Tigecycline was less active than minocycline, but both agents overcame most tetracycline resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11864948     DOI: 10.1093/jac/49.3.479

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  41 in total

1.  Comparison of Acinetobacter baumannii isolates from United Kingdom hospitals with predominant Northern European genotypes by amplified-fragment length polymorphism analysis.

Authors:  Richard P Spence; Tanny J K van der Reijden; Lenie Dijkshoorn; Kevin J Towner
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.

Authors:  D Milatovic; F-J Schmitz; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

3.  Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Rat Pneumonia Model.

Authors:  Ziad Tarazi; Mojgan Sabet; Michael N Dudley; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

4.  [Soft tissue infections in oral, maxillofacial, and plastic surgery. Bacterial spectra and antibiotics].

Authors:  A W Eckert; P Maurer; D Wilhelms; J Schubert
Journal:  Mund Kiefer Gesichtschir       Date:  2005-11

5.  Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline.

Authors:  F S Taccone; H Rodriguez-Villalobos; D De Backer; V De Moor; J Deviere; J-L Vincent; F Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

6.  Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents.

Authors:  Juliana Coelho; Neil Woodford; Mariya Afzal-Shah; David Livermore
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

7.  In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.

Authors:  Ellen S Moland; David W Craft; Seong-geun Hong; Soo-young Kim; Lucas Hachmeister; Shimon D Sayed; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

8.  Multidrug resistant acinetobacter.

Authors:  Vikas Manchanda; Sinha Sanchaita; Np Singh
Journal:  J Glob Infect Dis       Date:  2010-09

9.  In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.

Authors:  Paul G Higgins; Hilmar Wisplinghoff; Danuta Stefanik; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Observations on carbapenem resistance by minimum inhibitory concentration in nosocomial isolates of Acinetobacter species: an experience at a tertiary care hospital in North India.

Authors:  A Gaur; A Garg; P Prakash; S Anupurba; T M Mohapatra
Journal:  J Health Popul Nutr       Date:  2008-06       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.